Abstract
Objectives: This study evaluated the association between weight loss and change in depression among patients with type 2 diabetes mellitus (T2DM). Methods: Weight change from 2008 to 2009 among respondents (with and without T2DM) in the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) was calculated. Change in depression was calculated as change from 2008 to 2009 in Patient Health Questionnaire-9 (PHQ-9) scores. Respondents with weight loss (>1%, >3%, >5%) were compared with respondents with weight gain (≥1%). Multivariate regression adjusted for baseline characteristics. Results: Among those with T2DM, more respondents with weight loss (n = 779) improved their depression scores, compared with respondents with weight gain (n = 731): 32.9%, 36.9%, 39.8% for >1%, >3%, and >5% weight loss, respectively, vs. 28.7% for weight gain (p1%, 2.96 for >3%, and 3.31 for >5% weight loss, p
Highlights
Body weight is an important factor in the management of type 2 diabetes mellitus (T2DM) and health status
This study provides evidence of an additional benefit of weight loss that has not been explored previously among adults with T2DM
The study findings show an association between weight loss and improvement in depression over a 1-year period in adults with and without T2DM
Summary
Body weight is an important factor in the management of type 2 diabetes mellitus (T2DM) and health status. The majority (85%) of patients with T2DM are obese or overweight [1]. To add to this burden, some anti-diabetic medications, such as insulin, thiazolidinediones, and sulfonylureas, lead to an increase in body weight [2] [3]. Newer anti-diabetic therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, are associated with weight loss [4] [5]. Previous studies have shown that weight loss significantly improves glycemic control and lowers the risk of progression of T2DM [6] [7]. Other investigations have demonstrated that weight loss was related to better adherence to therapy [8], an effect that was durable for at least 10 years of metformin treatment [9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
